- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02387554
Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
June 11, 2015 updated by: Hanmi Pharmaceutical Company Limited
A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi
-
Bundang, Gyeonggi, Korea, Republic of
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- 19~45 years old
- Healthy men
Exclusion Criteria:
- Gastroentestinal disease affecting drug absorption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HGP0904+HGP0608+HGP1405
amlodipine + losartan + chlorthalidone
|
Other Names:
Other Names:
Other Names:
|
Active Comparator: HGP0904
amlodipine
|
Other Names:
|
Active Comparator: HGP0608
losartan
|
Other Names:
|
Active Comparator: HGP1405
chlorthalidone
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUClast
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
AUClast(Area under the curve to the last measurable concentration)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Cmax
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Cmax(maxium concentration)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCinf
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
AUCinf(Area under the curve to infinity)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Tmax
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Tmax(Time to maximum concentration)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
T1/2
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
T1/2(Terminal elimination half-life),
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
CL/F
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
CL/F(Apparent clearance)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Vz/F
Time Frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Vz/F(Apparent volume of distribution)
|
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Paticipants With Adverse Events
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
December 17, 2014
First Submitted That Met QC Criteria
March 11, 2015
First Posted (Estimate)
March 13, 2015
Study Record Updates
Last Update Posted (Estimate)
June 12, 2015
Last Update Submitted That Met QC Criteria
June 11, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Losartan
- Chlorthalidone
Other Study ID Numbers
- HM-ALCH-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension(HTN)
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
Quantum Genomics SAPRA Health SciencesTerminatedHypertension (HTN)United States, Canada
-
Servier RussiaNot yet recruiting
-
The First Affiliated Hospital of Xiamen UniversityRecruitingAF - Atrial Fibrillation | HTN-HypertensionChina
-
Servier RussiaCompleted
-
Medstar Health Research InstituteIndian Institute of Technology KanpurRecruitingDiabetes Mellitus | Pollution; Exposure | HTNIndia
-
Assiut UniversityCompletedHypertrophy, Left Ventricular | HTNEgypt
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
Clinical Trials on HGP0904
-
Hanmi Pharmaceutical Company LimitedCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedHealthyKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedHypertension | Erectile Dysfunction
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Hanmi Pharmaceutical Company LimitedCompleted